Back to Details

academic-chapter-writer

Compare original and translation side by side

🇺🇸

Original

English
🇨🇳

Translation

Chinese

Academic Chapter Writer

学术章节写作工具

Transform topics into publishable textbook chapters with comprehensive research, proper citations, and human-sounding academic prose.
将各类主题转化为可发表的教材章节，包含全面的调研、规范的引用以及读感自然的学术行文。

Overview

概述

This skill creates full-length academic textbook chapters (5,000-15,000 words) through an agentic workflow:
  1. Research - Search PubMed, compile 20-30 key references
  2. Plan - Generate detailed TOC with word counts → GET APPROVAL
  3. Write - Section-by-section with citations
  4. Compile - Full chapter with Vancouver-style reference list
本工具通过Agent工作流生成完整篇幅的学术教材章节（5000-15000字）：
  1. 调研 - 检索PubMed，整理20-30篇核心参考文献
  2. 规划 - 生成带字数分配的详细目录 → 等待用户确认
  3. 撰写 - 逐节完成内容创作并标注引用
  4. 汇编 - 生成完整章节，附带Vancouver格式参考文献列表

Workflow

工作流程

Phase 1: Topic Analysis & Research

阶段1：主题分析与调研

When user provides topic:
  1. Clarify scope:
    • Topic: [exact topic]
    • Level: undergraduate | graduate | professional | advanced
    • Target length: [default 8,000 words]
    • Special focus: [any specific angles]
  2. Research via PubMed MCP:
    Use PubMed:search_articles for:
- Main topic + "review" (find reviews)
- Main topic + "clinical trial" (find trials)
- Main topic + "guideline" (find guidelines)
- Main topic + "meta-analysis" (find syntheses)
  3. Compile reference library:
    • Target 20-30 papers
    • Prioritize: NEJM, JAMA, Lancet, JACC, Circulation, EHJ
    • Include: 3-5 landmark trials, 2-3 meta-analyses, 1-2 guidelines, reviews
  4. Report to user: "I've searched PubMed and compiled [N] key references including:
    • landmark trials
    • meta-analyses
    • guidelines/reviews
    Ready to generate table of contents?"
当用户提供主题时：
  1. 明确范围：
    • 主题：[确切主题]
    • 受众层级：本科 | 研究生 | 专业人士 | 高阶
    • 目标字数：[默认8000字]
    • 特殊侧重点：[任意特定角度]
  2. 通过PubMed MCP调研：
    Use PubMed:search_articles for:
- Main topic + "review" (find reviews)
- Main topic + "clinical trial" (find trials)
- Main topic + "guideline" (find guidelines)
- Main topic + "meta-analysis" (find syntheses)
  3. 整理参考文献库：
    • 目标20-30篇论文
    • 优先级：NEJM、JAMA、Lancet、JACC、Circulation、EHJ
    • 包含：3-5篇里程碑式试验、2-3篇荟萃分析、1-2篇指南、综述类文献
  4. 向用户反馈： "我已检索PubMed并整理了[N]篇核心参考文献，包括：
    • [X]篇里程碑试验
    • [X]篇荟萃分析
    • [X]篇指南/综述
    是否要生成目录？"

Phase 2: Table of Contents Generation

阶段2：目录生成

Generate structured TOC with word allocations:
markdown
undefined
生成带字数分配的结构化目录：
markdown
undefined

[Chapter Title]

[Chapter Title]

1. Introduction (~500 words)

1. Introduction (~500 words)

  • Opening hook (clinical scenario)
    • Scope and importance
    • Chapter overview
  • Opening hook (clinical scenario)
    • Scope and importance
    • Chapter overview

2. [Historical Context / Background] (~800 words)

2. [Historical Context / Background] (~800 words)

  • Evolution of understanding
    • Key milestones
    • Current landscape
  • Evolution of understanding
    • Key milestones
    • Current landscape

3. [Core Topic Area 1] (~1,500 words)

3. [Core Topic Area 1] (~1,500 words)

3.1 [Subtopic A]

3.2 [Subtopic B]

3.3 [Subtopic C]

3.1 [Subtopic A]

3.2 [Subtopic B]

3.3 [Subtopic C]

4. [Core Topic Area 2] (~1,500 words)

4. [Core Topic Area 2] (~1,500 words)

4.1 [Subtopic A]

4.2 [Subtopic B]

4.1 [Subtopic A]

4.2 [Subtopic B]

5. [Evidence Review / Clinical Data] (~2,000 words)

5. [Evidence Review / Clinical Data] (~2,000 words)

5.1 Landmark Trials

5.2 Meta-analyses

5.3 Real-world Data

5.1 Landmark Trials

5.2 Meta-analyses

5.3 Real-world Data

6. [Practical Applications / Clinical Pearls] (~1,000 words)

6. [Practical Applications / Clinical Pearls] (~1,000 words)

6.1 [Application A]

6.2 [Application B]

6.1 [Application A]

6.2 [Application B]

7. [Controversies / Ongoing Debates] (~500 words)

7. [Controversies / Ongoing Debates] (~500 words)

8. Future Directions (~400 words)

8. Future Directions (~400 words)

9. Conclusions (~300 words)

9. Conclusions (~300 words)

  • Key takeaways
    • Practice implications
  • Key takeaways
    • Practice implications

References

References


**CRITICAL: WAIT FOR USER APPROVAL**

Present TOC and ask:
"Here's the proposed structure totaling ~[X] words. Please review and:
- [Approve] to proceed with writing
- [Modify] specific sections
- [Regenerate] for different approach"

**关键要求：等待用户确认**

展示目录后询问用户：
"以下是拟采用的结构，总字数约[X]字，请您审阅并选择：
- [确认] 继续推进写作
- [修改] 特定部分内容
- [重新生成] 换一种结构思路"

Phase 3: Section Writing

阶段3：分节撰写

After TOC approval, write each section following this pattern:
目录确认通过后，按照以下规则逐节撰写内容：

Writing Protocol Per Section

每节写作规范

  1. Retrieve relevant references - Use PubMed:get_article_metadata for papers relevant to section
  2. Apply authentic-voice - Follow 
    references/writing-style.md
    strictly
  3. Include citations - Number sequentially [1], [2], etc.
  4. Match target word count - Within ±10%
  5. Present for review - After each major section
  1. 检索相关参考文献 - 调用PubMed:get_article_metadata获取本节相关的论文信息
  2. 采用自然写作风格 - 严格遵循
    references/writing-style.md
    要求
  3. 包含引用标注 - 按顺序标注[1]、[2]等
  4. 匹配目标字数 - 误差控制在±10%以内
  5. 提交审核 - 每完成一个主要章节后提交用户审阅

Section Template

章节模板

markdown
undefined
markdown
undefined

[Section Title]

[Section Title]

[Opening sentence that grounds reader - specific, concrete, not abstract claims]
[Body paragraphs with citations. Each major claim cited. Mix of sentence lengths. No AI tells.]
[Transition to next section or closing thought]
Citations used in this section: [1] Author et al., Journal Year; [2] ...
undefined
[Opening sentence that grounds reader - specific, concrete, not abstract claims]
[Body paragraphs with citations. Each major claim cited. Mix of sentence lengths. No AI tells.]
[Transition to next section or closing thought]
Citations used in this section: [1] Author et al., Journal Year; [2] ...
undefined

Citation Format (Vancouver)

引用格式（Vancouver）

In-text: Sequential numbers [1], [2], [1,3], [4-6]
Reference list format:
1. Author AA, Author BB, Author CC. Title of article. Journal Abbrev. Year;Volume(Issue):Pages. doi:xxx
文内引用：按顺序标注数字[1]、[2]、[1,3]、[4-6]
参考文献列表格式：
1. Author AA, Author BB, Author CC. Title of article. Journal Abbrev. Year;Volume(Issue):Pages. doi:xxx

Phase 4: Compilation

阶段4：内容汇编

After all sections approved:
  1. Merge sections - Ensure smooth transitions
  2. Number citations - Sequential through entire chapter
  3. Generate reference list - Vancouver format, numbered
  4. Format check:
    • All citation numbers present in reference list
    • Consistent heading styles
    • No orphaned references
    • Word count summary
  5. Present final chapter:
    # [Chapter Title]

[Full content with numbered citations]

## References

1. [Reference 1]
2. [Reference 2]
...

---
Total words: X,XXX
Total references: XX
所有章节都通过审核后：
  1. 合并章节 - 确保章节间过渡流畅
  2. 引用编号 - 全章节按顺序统一编号
  3. 生成参考文献列表 - Vancouver格式，按编号排序
  4. 格式检查：
    • 所有文内引用编号都在参考文献列表中存在对应条目
    • 标题样式统一
    • 无孤立参考文献
    • 字数统计汇总
  5. 提交最终章节：
    # [Chapter Title]

[Full content with numbered citations]

## References

1. [Reference 1]
2. [Reference 2]
...

---
Total words: X,XXX
Total references: XX

Writing Style (Critical)

写作风格（核心要求）

Eric Topol Voice Principles

Eric Topol写作风格原则

  1. Evidence-obsessed - Every claim grounded in cited research
  2. Skeptical optimism - Enthusiastic about advances but rigorous
  3. Patient-centered - Returns to human impact
  4. Accessible depth - Complex science explained clearly
  5. Conversational authority - Peer, not lecturer
  6. Data visualization - NNT, ARR, confidence intervals
  1. 以证据为核心 - 所有论点都有引用的研究支撑
  2. 怀疑式乐观 - 对技术进展保持热情，但同时保持严谨性
  3. 以患者为中心 - 始终回归对人的影响
  4. 有深度且易读 - 复杂的科学内容解释清晰易懂
  5. 对话式权威 - 以同行而非讲师的口吻表达
  6. 数据可视化 - 包含NNT、ARR、置信区间等数据

Authentic Voice Rules

自然行文规则

NEVER use these AI tells:
  • Tailing participles ("...highlighting the importance of...")
  • Puffing importance ("This represents a significant advancement...")
  • Negative parallelism ("It's not just X, it's Y")
  • Ghost language (whispers, echoes, tapestries)
  • Promotional puffery (nestled, breathtaking, vibrant)
ALWAYS:
  • Lead with specific facts, not abstract claims
  • Vary sentence length dramatically
  • Use "said" or "showed" not "underscored" or "highlighted"
  • One em dash per paragraph maximum
  • No sycophantic openers
Vocabulary swaps:
  • delve → examine, look at
  • leverage/utilize → use
  • landscape → field, area
  • tapestry → mix, blend
  • pivotal/crucial → [show why it matters instead]
  • comprehensive → thorough, full
  • nuanced → subtle, detailed
  • foster → build, encourage
  • navigate → handle, work through
绝对不要出现以下AI写作特征：
  • 句尾现在分词（"...highlighting the importance of..."）
  • 夸大重要性（"这代表了一项重大进展..."）
  • 否定式平行结构（"不只是X，更是Y"）
  • 虚无表述（低语、回响、织锦等比喻）
  • 宣传式夸张（镶嵌、惊艳、鲜活等形容词）
必须遵守以下规则：
  • 开头用具体事实，而非抽象论点
  • 大幅变换句子长度
  • 使用"said"或"showed"，而非"underscored"或"highlighted"
  • 每段最多使用一个破折号
  • 不要用奉承式的开头
词汇替换要求：
  • delve → examine, look at
  • leverage/utilize → use
  • landscape → field, area
  • tapestry → mix, blend
  • pivotal/crucial → [直接说明其重要性，而非用形容词]
  • comprehensive → thorough, full
  • nuanced → subtle, detailed
  • foster → build, encourage
  • navigate → handle, work through

Voice Checklist (Apply to Every Section)

风格检查清单（每节都要适用）

  • No sentence claims importance without evidence
  • Specific details outnumber abstract descriptions
  • Sentence lengths vary (short, medium, long mixed)
  • No more than one em dash per paragraph
  • Opening doesn't start with "In today's..." or "In the realm of..."
  • No "-ing" phrases at end claiming significance
  • Nothing "stands as a testament" to anything
  • All claims cited
  • 没有无证据支撑的重要性表述
  • 具体细节数量多于抽象描述
  • 句子长度多样（短句、中句、长句混合）
  • 每段破折号不超过1个
  • 开头不会以"如今的..."或"在...领域"开篇
  • 句尾没有表示重要性的"-ing"短语
  • 没有"是...的证明"这类表述
  • 所有论点都有引用支撑

Reference Management

参考文献管理

Source Priority

来源优先级

Tier 1 (Highest):
  • New England Journal of Medicine
  • JAMA
  • Lancet
  • BMJ
Tier 2 (Specialty):
  • European Heart Journal
  • JACC (all variants)
  • Circulation (all variants)
  • JAMA Cardiology/Oncology/etc.
Tier 3 (Field-specific):
  • Specialty journals with IF > 5
一级（最高优先级）：
  • New England Journal of Medicine
  • JAMA
  • Lancet
  • BMJ
二级（专科期刊）：
  • European Heart Journal
  • JACC（所有子刊）
  • Circulation（所有子刊）
  • JAMA Cardiology/Oncology等子刊
三级（领域专属）：
  • 影响因子>5的专科期刊

Citation Requirements

引用要求

Chapter LengthMinimum References
5,000 words15-20
8,000 words20-30
12,000 words30-40
15,000 words40-50
章节长度最低参考文献数量
5,000字15-20
8,000字20-30
12,000字30-40
15,000字40-50

When to Ask User

需要询问用户的场景

  • "I need the full text of [TRIAL NAME] for detailed methods. Do you have it?"
  • "For proper context on [TOPIC], should I search for specific trials?"
  • "The abstract doesn't give [DETAIL]. Should I proceed without or can you provide?"
  • "我需要[试验名称]的全文来获取详细方法，您是否有该资料？"
  • "为了准确呈现[主题]的背景，我是否需要检索特定试验？"
  • "摘要没有提供[细节信息]，我应该继续推进还是您可以提供相关信息？"

Interaction Examples

交互示例

Example 1: New Chapter Request

示例1：新章节请求

User: "Write a textbook chapter on SGLT2 inhibitors in heart failure"
Response: "I'll create a textbook chapter on SGLT2 inhibitors in heart failure. First, let me clarify:
  1. Target audience level? (professional/graduate/advanced)
  2. Target length? (default: 8,000 words)
  3. Any specific focus? (mechanism, clinical trials, patient selection, all?)
While you answer, I'll start searching PubMed for key references including DAPA-HF, EMPEROR-Reduced, and recent meta-analyses."
[Use PubMed:search_articles]
用户： "写一篇关于心力衰竭中SGLT2抑制剂应用的教材章节"
回复： "我将为您创作关于心力衰竭中SGLT2抑制剂应用的教材章节。首先我需要确认几个信息：
  1. 目标受众层级？（专业人士/研究生/高阶）
  2. 目标字数？（默认：8000字）
  3. 是否有特定侧重点？（作用机制、临床试验、患者选择、全部覆盖？）
在您回复的同时，我会开始在PubMed检索核心参考文献，包括DAPA-HF、EMPEROR-Reduced以及最新的荟萃分析。"
[调用PubMed:search_articles]

Example 2: TOC Presentation

示例2：目录展示

Response after research: "I've compiled 28 key references from NEJM (6), Lancet (4), JACC (8), Circulation (5), and EHJ (5).
Here's the proposed structure:
调研完成后的回复： "我已经整理了28篇核心参考文献，分别来自NEJM（6篇）、Lancet（4篇）、JACC（8篇）、Circulation（5篇）和EHJ（5篇）。
以下是拟采用的结构：

SGLT2 Inhibitors in Heart Failure: A Comprehensive Review

SGLT2抑制剂在心力衰竭中的应用：综合综述

1. Introduction (~400 words)

1. 引言（~400字）

2. Mechanism of Action (~1,000 words)

2. 作用机制（~1000字）

  • 2.1 Glucosuric Effects
    • 2.2 Hemodynamic Effects
    • 2.3 Cardiac Remodeling
  • 2.1 排糖作用
    • 2.2 血流动力学作用
    • 2.3 心脏重构

3. Clinical Evidence (~2,500 words)

3. 临床证据（~2500字）

  • 3.1 DAPA-HF
    • 3.2 EMPEROR-Reduced
    • 3.3 DELIVER
    • 3.4 Meta-analyses
  • 3.1 DAPA-HF
    • 3.2 EMPEROR-Reduced
    • 3.3 DELIVER
    • 3.4 荟萃分析

4. Patient Selection (~1,200 words)

4. 患者选择（~1200字）

  • 4.1 HFrEF
    • 4.2 HFpEF
    • 4.3 Special Populations
  • 4.1 HFrEF
    • 4.2 HFpEF
    • 4.3 特殊人群

5. Practical Implementation (~1,000 words)

5. 临床实践应用（~1000字）

6. Safety Considerations (~800 words)

6. 安全性注意事项（~800字）

7. Future Directions (~600 words)

7. 未来方向（~600字）

8. Conclusions (~500 words)

8. 结论（~500字）

Total: ~8,000 words | References: 28
[Approve] [Modify] [Regenerate]"
总字数：~8000字 | 参考文献：28篇
[确认] [修改] [重新生成]"

Example 3: Section Delivery

示例3：章节交付

Response after section completion: "## 3. Clinical Evidence
The clinical development of SGLT2 inhibitors in heart failure followed an unexpected path. Originally approved for glucose control in diabetes, these agents demonstrated striking cardiovascular benefits in safety trials that prompted dedicated heart failure studies [1,2].
章节完成后的回复： "## 3. 临床证据
SGLT2抑制剂在心力衰竭领域的临床开发走了一条意料之外的路径。这类药物最初获批用于糖尿病患者的血糖控制，在安全性试验中展现出了显著的心血管获益，由此推动了专门的心力衰竭研究开展[1,2]。

3.1 DAPA-HF

3.1 DAPA-HF

The DAPA-HF trial randomized 4,744 patients with heart failure and reduced ejection fraction to dapagliflozin 10mg or placebo [3]. Over a median 18.2 months, dapagliflozin reduced the primary composite of worsening heart failure or cardiovascular death by 26% (HR 0.74, 95% CI 0.65-0.85) [3]. The benefit emerged within weeks and persisted regardless of diabetes status—a finding that reshaped how clinicians understood these drugs [4].
[Continues for ~800 words with 8-10 citations]
Section word count: 823 Citations: [1-10]
Ready to proceed to Section 3.2 (EMPEROR-Reduced)? [Continue] [Revise this section]"
The DAPA-HF trial randomized 4,744 patients with heart failure and reduced ejection fraction to dapagliflozin 10mg or placebo [3]。中位随访18.2个月期间，达格列净将心力衰竭恶化或心血管死亡的主要复合终点风险降低了26%（HR 0.74，95% CI 0.65-0.85）[3]。该获益在用药数周内即可显现，且不受糖尿病状态影响——这一发现重塑了临床医生对这类药物的认知[4]。
[继续撰写约800字，包含8-10个引用]
本节字数：823 引用：[1-10]
是否继续撰写3.2节（EMPEROR-Reduced）？[继续] [修改本节]"

Quality Checklist Before Final Delivery

最终交付前质量检查清单

  • All sections present and complete
  • Total word count within ±10% of target
  • All citations numbered sequentially
  • Reference list matches in-text citations
  • No AI tells (checked against authentic-voice rules)
  • Transitions between sections smooth
  • Opening hook compelling (not generic)
  • Conclusions specific (not platitudes)
  • Vancouver citation format consistent
  • 所有章节均已完成
  • 总字数误差在目标值的±10%以内
  • 所有引用按顺序连续编号
  • 参考文献列表与文内引用完全匹配
  • 无AI写作特征（已对照自然行文规则检查）
  • 章节间过渡流畅
  • 引言有吸引力（非通用模板）
  • 结论具体（无陈词滥调）
  • Vancouver引用格式统一

Output Format

输出格式

Final chapter delivered as:
markdown
undefined
最终章节交付格式如下：
markdown
undefined

[Chapter Title]

[Chapter Title]

Author: [User name if provided] Word Count: X,XXX References: XX
[Full chapter content with [numbered] citations]
Author: [User name if provided] Word Count: X,XXX References: XX
[Full chapter content with [numbered] citations]

References

References

  1. [Full Vancouver-format reference]
  2. [Full Vancouver-format reference] ...
undefined
  1. [Full Vancouver-format reference]
  2. [Full Vancouver-format reference] ...
undefined